Syed Ibrahim Bukhari: From Conventional Therapy to Gene-Based Approaches in Hemophilia Care
Syed Ibrahim Bukhari, Clinical Fellow at The Hospital for Sick Children, shared a post on LinkedIn:
“In honor of World Hemophilia Day 2025, I had the privilege of presenting on ‘Hemophilia Management: Current Standards and Emerging Frontiers’ at the National Institute of Child Health (NICH) in Karachi.
The session focused on the critical importance of specialized care for pediatric patients and the evolving landscape of treatment.
Key Highlights from the Presentation:
The Core Challenge: Hemophilia A and B are X-linked recessive disorders characterized by deficiencies in clotting factors VIII and IX, respectively, leading to prolonged bleeding and potential joint damage.
Diagnosis and Severity: We discussed the importance of classifying severity based on factor levels—Severe (<1 percent), Moderate (1-5 percent), and Mild (5-40 percent)—to tailor treatment effectively.
Management Pillars: The talk emphasized the ‘P.R.I.C.E’ protocol for acute bleeds (Protection, Rest, Ice, Compression, Elevation) alongside prompt factor replacement therapy.
Prophylaxis versus Episodic Care: A major focus was the shift toward prophylaxis (regular treatment to prevent bleeds) as the gold standard for preventing chronic hemophilic arthropathy and improving quality of life.
Inhibitors and Complications: We addressed the challenge of inhibitors, where the body’s immune system reacts against replacement factors, necessitating advanced bypass agents or immune tolerance induction.
Future Frontiers: I shared insights into the potential of gene therapy and non-factor replacement therapies, like Emicizumab, which are revolutionizing how we approach long-term care.
Thank you to the team at NICH for organizing this event and for their unwavering commitment to our young patients in Karachi.
Together, we can strive for a future where ‘Access for All’ becomes a reality.”

See more in the gallery.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring
-
Aug 11, 2026, 14:30Bharat Moyal: The New KDIGO 2026 Approach to Anemia in CKD
-
Aug 11, 2026, 14:16Rayan Ahmed: Master Blood Films and Pathology Online
-
Aug 11, 2026, 13:53Steven Lubega: Why Are Healthy Newborns Born Poorly Equipped To Stop Bleeding?
-
Aug 11, 2026, 13:47Why Stroke Risk Changes During Pregnancy – International Journal of Stroke